Optimizing Care for Metastatic Non-Small Cell Lung Cancer Without Driver Mutations : Episode 11

Opinion

Video

August 12, 2024

Clinical Factors Impacting Immunotherapy Response and Optimizing Patient Selection

Author(s):

Mark Socinski, MD,John Heymach, MD, PhD

A panel of experts on non-small cell lung cancer outline factors that impact how well patients respond to immunotherapy.

EP: 1.Biomarker Testing and Guideline-Recommended Care in mNSCLC

EP: 2.Strategies to Increase Biomarker Testing Rates

EP: 3.Limitations on Optimal Biomarker Testing Rates

EP: 4.Impact of Biomarker Testing on Treatment Selection and Outcomes

EP: 5.Key Challenges and Unmet Needs in Newly Diagnosed Driver-Negative mNSCLC

EP: 6.NCCN Recommendations by PD-L1 Expression Level

EP: 7.Limitations of NCCN PD-L1 Expression Recommendations

EP: 8.Emerging Data and Evidence for Dual Immunotherapy plus Chemotherapy in First-Line mNSCLC

EP: 9.Genetic Alterations Impacting Treatment Response and Biomarker Testing Rates in mNSCLC

EP: 10.Molecular Characteristics Beyond Mutations Influencing Immunotherapy Response

EP: 11.Clinical Factors Impacting Immunotherapy Response and Optimizing Patient Selection

EP: 12.Overcoming Immunotherapy Resistance: Identifying Non-Responders and Novel Approaches

EP: 13.Key Takeaways on Enhancing Outcomes for mNSCLC Without Targetable Driver Mutations

Video content above is prompted by the following questions:

Outside of biomarkers, what clinical factors also lead to immune checkpoint inhibitor therapy underperformance?
How can patient selection be optimized among those less likely to respond to immune checkpoint inhibitor therapy?

Related Videos

5 experts are featured in this series.

Edgardo S. Santos, MD, FACP, FASCO

5 experts are featured in this series.

Related Content

Ryan Nguyen, DO

January 1st 2025

AI in Oncology: Opportunities and Challenges for NSCLC

Skylar Jeremias

Ryan Nguyen, DO, University of Illinois Chicago, highlights the importance of personalized care for patients who have non–small cell lung cancer (NSCLC) and the potential of artificial intelligence (AI) in oncology, while cautioning against its limitations, including the risk of unsupported recommendations.

WCLC Highlights Thumbnail

December 27th 2024

ICYMI: Highlights From WCLC 2024

The 2024 World Conference on Lung Cancer (WCLC) took place in San Diego, California, from September 7 to 10, 2024.

Ryan Nguyen, MD

December 23rd 2024

Precision Oncology in NSCLC: Overcoming Patient Selection Barriers

Skylar Jeremias

Ryan Nguyen, DO, physician and researcher at the University of Illinois Chicago, emphasizes the transformative impact of immunotherapy in non–small cell lung cancer (NSCLC) and the need for precise biomarkers and equitable access to advanced treatments through systemic testing protocols.

NSCLC Thumbnail

December 20th 2024

Top 5 NSCLC Content for 2024

Our top content for the year highlight many challenges the field of non–small cell lung cancer (NSCLC) encountered, with data showing both setbacks in clinical trial results and advancements in screening recommendations for at-risk patients.

FDA approval. | Image Credit: Pawel - stock.adobe.com

December 19th 2024

Ensartinib Receives FDA Approval for ALK-Positive Locally Advanced or Metastatic NSCLC

Cameron Santoro

The FDA has approved ensartinib in adult patients with anaplastic lymphoma kinase (ALK)–positive locally advanced or metastatic non–small cell lung cancer (NSCLC) naive to ALK treatment.

Syringe and vials | Image credit: Aliaksandr Marko – stock.adobe.com

December 17th 2024

FDA Rejects Subcutaneous Amivantamab for NSCLC Over Manufacturing Concerns

Hayden E. Klein

Subcutaneous amivantamab joins a growing list of drugs receiving complete response letters due to manufacturing facility issues.

Related Content

Ryan Nguyen, DO

January 1st 2025

AI in Oncology: Opportunities and Challenges for NSCLC

Skylar Jeremias

Ryan Nguyen, DO, University of Illinois Chicago, highlights the importance of personalized care for patients who have non–small cell lung cancer (NSCLC) and the potential of artificial intelligence (AI) in oncology, while cautioning against its limitations, including the risk of unsupported recommendations.

WCLC Highlights Thumbnail

December 27th 2024

ICYMI: Highlights From WCLC 2024

The 2024 World Conference on Lung Cancer (WCLC) took place in San Diego, California, from September 7 to 10, 2024.

Ryan Nguyen, MD

December 23rd 2024

Precision Oncology in NSCLC: Overcoming Patient Selection Barriers

Skylar Jeremias

Ryan Nguyen, DO, physician and researcher at the University of Illinois Chicago, emphasizes the transformative impact of immunotherapy in non–small cell lung cancer (NSCLC) and the need for precise biomarkers and equitable access to advanced treatments through systemic testing protocols.

NSCLC Thumbnail

December 20th 2024

Top 5 NSCLC Content for 2024

Our top content for the year highlight many challenges the field of non–small cell lung cancer (NSCLC) encountered, with data showing both setbacks in clinical trial results and advancements in screening recommendations for at-risk patients.

FDA approval. | Image Credit: Pawel - stock.adobe.com

December 19th 2024

Ensartinib Receives FDA Approval for ALK-Positive Locally Advanced or Metastatic NSCLC

Cameron Santoro

The FDA has approved ensartinib in adult patients with anaplastic lymphoma kinase (ALK)–positive locally advanced or metastatic non–small cell lung cancer (NSCLC) naive to ALK treatment.

Syringe and vials | Image credit: Aliaksandr Marko – stock.adobe.com

December 17th 2024

FDA Rejects Subcutaneous Amivantamab for NSCLC Over Manufacturing Concerns

Hayden E. Klein

Subcutaneous amivantamab joins a growing list of drugs receiving complete response letters due to manufacturing facility issues.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions